Willingness to pay for one quality-adjusted life year in Iran 14 Economics 1402 Applied Economics 11 Medical and Health Sciences 1117 Public Health and Health Services by Moradi, N. et al.
Moradi et al. Cost Eff Resour Alloc            (2019) 17:4  
https://doi.org/10.1186/s12962-019-0172-9
RESEARCH
Willingness to pay for one quality-adjusted 
life year in Iran
Najmeh Moradi1* , Arash Rashidian2, Shirin Nosratnejad3, Alireza Olyaeemanesh4, Marzieh Zanganeh5 
and Leila Zarei6
Abstract 
Background: Recent years have witnessed a strong tendency to apply economic evidence as a guide for making 
health resource allocation decisions, especially those related to reimbursement policies. One such measure is the use 
of the cost-effectiveness threshold as a benchmark. This study explored the threshold for use in the health system of 
Iran by determining society’s preferences.
Methods: A cross-sectional household survey based on the contingent valuation method was administered to a rep-
resentative general population of 1002 in Tehran, Iran from April to June 2015. The survey was intended to estimate 
the respondents’ willingness-to-pay (WTP) preferences for one quality-adjusted life year (QALY) gained. The valuation 
scenarios featured 12 vignettes on mild to severe diseases that can change people’s quality of life. The mean of WTP 
for QALY was estimated using different health instruments, and the determinants of such willingness were analyzed 
using the Heckman selection model.
Results: WTP for QALY varied depending on the severity of a disease and the instrument used to determine health 
preferences. Mean low health state value were associated with high valuation. The best estimated WTP values ranged 
from US$1032 to US$2666 and 0.22–0.56 of Iran’s local gross domestic product (GDP) per capita in 2014. Except for 
educational level, significant variables differed across different disease scenarios. Generally, a high health state valu-
ation for target diseases, high income, high educational level, and being married were associated with high WTP for 
QALY.
Conclusion: From the general public’s perspective, the monetary value of QALY for mild to severe diseases with no 
risk of death was less than one GDP per capita. Therefore, the obtained valuation range is recommended as reference 
only for the adoption of interventions designed to improve quality of life. Future studies should estimate the thresh-
old of interventions for life-threatening diseases or formulate transparent policies in such contexts.
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Background
Decision making on health care resource allocation is 
an overly complicated and challenging process because 
of the complexity of health care systems, the direct and 
indirect effects of a policy decision on other divisions of 
such systems, and the scarcity of health care resources, 
particularly financial resources. In view of resource con-
straints, health care systems often tend to make decisions 
that maximize people’s health at the highest efficiency. 
To achieve these goals, decision makers have employed 
different criteria and decision analytical tools, such as 
health economic evaluation [1–3]. Health economic 
evaluation plays a valuable role in the establishment of 
health care priorities by assisting decision makers in allo-
cating limited health care resources to interventions that 
present the greatest health gain for an entire society [4]. 
The most common type of health economic evaluation is 
cost-effectiveness analysis (CEA), which evaluates alter-
native interventions in terms of their differences in cost 
and quality-adjusted life year (QALY) gained [5]. A major 
Open Access
Cost Effectiveness and 
Resource Allocation
*Correspondence:  najme.moradi@gmail.com 
1 Health Management and Economics Research Center, Iran University 
of Medical Sciences, Tehran, Iran
Full list of author information is available at the end of the article
Page 2 of 10Moradi et al. Cost Eff Resour Alloc            (2019) 17:4 
shortcoming of CEA, however, is that the result of anal-
ysis is only a numerical value (i.e., incremental cost per 
QALY) that indicates, in comparison with alternatives, 
which QALYs are cheaper. This is minimally compre-
hensible to policy makers and fails to offer an acceptable 
solution to the issue of which intervention offers the best 
value for money or how much cost per QALY should be 
acceptable and worth investing in given the resources 
available to a national health care system [6]. Address-
ing this issue necessitates establishing a cost-effectiveness 
(CE) threshold as a benchmark at the national level. As 
expected by Eichler [7], the CE threshold has increasingly 
emerged as a requirement in countries that have intro-
duced economic evaluation guidelines into their health 
care systems and have introduced CE results as a fourth 
hurdle alongside efficacy, quality, and safety, in deci-
sion making regarding pharmaceutical reimbursement 
[8, 9]. Iran likewise exhibits a strong inclination to apply 
economic evidence as basis for making resource alloca-
tion decisions, especially those related to reimburse-
ment policies [10–12]. This tendency is demonstrated 
by the establishment of a health technology assessment 
office in Iran’s Health Ministry in 2007, the formulation 
of pharmacoeconomic evaluation guidelines by Iran’s 
Food and Drug Administration for the inclusion of new 
drugs in the national drug list, the growing number of 
CEA studies on medical equipment and treatments, 
and student admissions in the fields of health econom-
ics, pharmacoeconomics, and health technology assess-
ment [10–12]. In practice, however, Iran applies neither a 
transparent decision criterion nor a CE threshold or any 
evidence-based approach to reimbursement decisions 
[13]. The only measure used in the country is the World 
Health Organization’s (WHO) recommendation for 
choosing cost-effective interventions based on a country 
gross domestic product (GDP) per capita. So an inter-
vention is very cost-effective/cost-effective if the incre-
mental cost effectiveness ratio fell below one/between 
1 to 3 times a country’s GDP per capita. This threshold 
taken from 2001 WHO Commission on Macroeconom-
ics and Health (CMH) report which stated “according to 
some estimation, each life year is valued at around three 
times the annual earnings”. So, based on this statement, 
spending per capita estimated value to achieve one extra 
healthy life year was reasonable [14, 15].
The simplicity and easy use of WHO criterion increase 
the employing it worldwide particularly by low/middle 
income countries. A review by leech on studies which 
cited the WHO EC threshold during 2000–2015 showed 
that 66% of studies in low-/middle income countries used 
it [16]. In spite of, growing use of WHO CE threshold 
value, due to lacks a clarification on the value deriva-
tion, the concerns around applying it in policy making 
context are raising [16–18]. Similarly, in Iran health sys-
tem context, there is a general consensus to establish an 
evidence-based local CE threshold value with the aim 
of applying CEA results in practice to maximize health 
and efficiency. Given the limitations of the WHO’s rec-
ommendation and the drawbacks of other approaches to 
obtaining the CE threshold including the weaknesses of 
the league table to apply in practice and lack of explicit 
supported evidences in revealed past health resource 
allocation decisions, the stated-preference approach 
was chosen as the best method to explore an evidence-
based CE threshold for use in Iran health care system 
[19]. Therefore, this study aimed to investigate Iranian 
preferences for monetary value for QALY through elicit-
ing individuals’ maximum willingness to pay (WTP) for a 
given health utility gain and also to assess its consistency 
WHO CE threshold value.
Methods
Study design and sampling
To determine WTP for the QALY gained from interven-
tions intended to improve quality of life, a cross-sectional 
household survey and face-to-face interviews were con-
ducted with a representative general population of 1002 
in Tehran, Iran from April to June 2015. The sample was 
selected from 22 municipal regions of Tehran via two-
stage cluster sampling, with consideration for probability 
proportional to size sampling [20]. The inclusion criteria 
were being a household member aged 18–79  years old, 
having Iranian nationality, being able to understand and 
speak Farsi, and having no mental disability. For the 
interviews, eligible respondents were chosen randomly 
on the basis of the detailed protocol. The protocol of 
study was approved by the Ethics Committee of Shahid 
Beheshti University of Medical Sciences. The Verbal con-
sent was approved by the Committee and it was obtained 
from participants according to a step-by step guide which 
was developed for that. Respondents who were reluctant 
to be interviewed were substituted with the respondents 
most similar to the hesitant individuals in terms of age 
and gender.
Preference elicitation scenarios
To elicit preferences, 14 hypothetical disease scenarios 
were presented to 29 individuals during a pilot study, 
and each of the respondents was asked to value at least 
two scenarios. These hypothetical scenarios were dis-
ease vignettes that vary in intensity (mild, moderate, and 
severe) and course of a given disease over time (Table 1). 
They were based on empirical evidence, in which records 
(cards) indicate two types of information: disease labels 
with specific descriptions of diseases and generic descrip-
tions of health states targeted within the framework of 
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the five-level EuroQol five-dimension questionnaire (EQ-
5D-5L) plus one extra dimension on cognitive function-
ing (i.e., the five-level six-dimension questionnaire or 
EQ-6D-5L) [21].
On the basis of the pilot study’s results, corrections 
were made to the questionnaire. For example, two out 
of the 14 scenarios (i.e., nail infection and athlete’s foot) 
were excluded because they were deemed insufficiently 
important, and payment questions were changed from 
open-ended payment questions to closed-ended ones. 
To increase the validity of the responses, we classified 
the remaining 12 disease vignettes into six groups (A–F). 
Each group consisted of four scenarios: one featuring 
permanent severe chronic disease (CVA), spinal impair-
ment, or dementia; another featuring permanent mild 
chronic disease; and two others featuring recurrent mild 
diseases. Each scenario was indicated in two of the classi-
fication groups, as shown in (Fig. 1). Then, each classifica-
tion group was attached to the questionnaire (Additional 
file 1), which was randomly administered to the respond-
ents, according to the detailed protocol described in the 
study design and sampling section.
Table 1 Descriptions of disease vignettes. Source: Ref. [21]
No. Disease EQ-6D-5L Course 
of disease 
over time
1 Otitis media, yearly recurrent (chronic otitis media) 112,412 Recurrent
2 Migraine, monthly recurrent 124,413 Recurrent
3 Allergic rhinitis, seasonal (hay fever), yearly recurrent 111,211 Recurrent
4 Gastritis, 6 months, untreated (inflammation of the stomach lining) 112,311 Recurrent
5 Cystitis, chronic recurrent (recurrent cystitis) 112,311 Recurrent
6 Athlete’s foot, untreated (tinea pedis) 111,211 Chronic
7 Infection of the nails, chronic, untreated, onychomycosis 111,211 Chronic
8 Eczema, chronic permanent (dermatitis atopic) 112,211 Chronic
9 Back and neck pain 322,311 Chronic
10 Depression, mild 112,131 Chronic
11 CVA/stroke, moderate impairments 333,323 Chronic
12 Dementia, severe 345,235 Chronic
13 Hip fracture 444,311 Chronic
14 Spinal cord lesion, low (stable phase) 544,321 Chronic
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Fig. 1 Grouping of disease scenarios
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Preference elicitation techniques
We used the visual analogue scale (VAS), the time 
trade-off (TTO) technique, and the contingent valua-
tion method (CVM) to determine the health and WTP 
preferences of the respondents [22–24]. To identify 
health preferences, the respondents were asked to indi-
cate their current health states by using the VAS, after 
which an assigned vignette was shown to the respond-
ents, who were then asked to imagine themselves in 
such a situation. After this visualization task, they were 
asked to re-rate their health states by using the VAS. 
For the TTO measurement, we asked the respondents 
to imagine themselves having a target disease and state 
the maximum time that they are willing to sacrifice to 
avoid being in such a situation for the rest of their life. 
Two durations were used in this “trading” exercise: one 
adjusted with age-specific life expectancy and the other 
a fixed 10-year period [25]. Finally, the respondents were 
asked to indicate their maximum WTP for a hypotheti-
cal treatment that would cure them of their hypothetical 
disease. To reduce any biases associated with the hypo-
thetical nature of stated WTP studies, this section was 
design according to key aspects of CV construction sug-
gested by Smith -from a scenario construction to mode 
of administration [26]. For example, the disease scenarios 
were based on the patients’ experiences and among dif-
ferent payment vehicles, the out of pocket payment cho-
sen as an appropriate one because it is a common form 
of payment in Iran health system and OOP constitute a 
high share of total health expenditure, insofar as, reduc-
ing it was one of the main objective of Iran health trans-
formation plan [27] Also, the payment card (PC) method, 
accompanied with a follow-up open-ended question, was 
chosen to identify WTP [28]. Among the commonly used 
closed-ended questions of CVM, PC questions were cho-
sen for this work primarily because such questions cover 
a diversity of diseases in each disease group, from mild 
to severe, which in turn, correspond to a wide range of 
money amounts that respondents would be willing to 
pay. Another reason for the choice was to avoid respond-
ent fatigue and confusion in the valuation of the four dis-
ease scenarios; such conditions give rise to the bargaining 
tendency observed in the two other CVM methods (i.e., 
dichotomous choice and bidding game formats). To min-
imize biases arising from ranges, based on pilot test, we 
designed a range of 18 bid amounts on the basis of their 
appropriateness for all scenarios (The bid amounts are 
available in Additional file  1). The range put forward in 
this research was US$333 to US$83,333, which is equal 
to 0.07–17.5 of Iran’s local GDP per capita in 2014. So 
as not to constrain the respondents with our range, the 
“less than” and “more than” value options were incor-
porated into the lower and upper limits of the range. 
Then the follow up question was asked to determine the 
exact amount. The bid amounts were presented only to 
the respondents who were willing to pay even meager 
amounts to avoid health utility losses. Moreover, to mini-
mize hypothetical bias, reminding Budget constraint and 
asking follow up question to identify source payment 
used as ex-ante and ex-post approaches, respectively. As 
for the individuals with zero responses, their reasons for 
their unwillingness to pay were ascertained.
Data analysis
We used the chained approach in estimating the mean 
of WTP for one QALY in different scenarios. We then 
investigated the factors associated with such willingness 
as follows. We identified independent factors, including 
the socioeconomic and demographic characteristics of 
the respondents, the disease scenario familiarity/expe-
rience, hospitalization experience within the past year, 
near-death experience from a year before, and existence 
of a chronic disease or disability (physical or mental). The 
Heckman selection model was then used to probe into 
the factors associated with WTP for QALY [29, 30].
Data management and analysis were conducted using 
MS Excel 2010 and Stata/MP.
Results
Descriptive statistics
As previously stated, 1002 household members were 
interviewed using the designed questionnaire. The sam-
ple replacement was 8.2%. The mean age of the respond-
ents was 43 years old, and 41% of them were male. The 
general characteristics of the sample are presented in 
Table 2.
Health and WTP preferences of respondents
The respondents’ preferences, including those for health 
and WTP, are shown in Table  3. The table includes the 
mean health state valuation derived through the VAS 
and TTO measurements for each disease scenario before 
and after the presentation of the scenarios. The respond-
ents assigned the lowest health state value to the spinal 
cord lesion scenario. The scenario with the highest mean 
value was allergic rhinitis, followed by otitis media. The 
mean WTP values ranged from US$560 for otitis media 
to US$11,944 for CVA. Out of the 12 disease scenarios, 
more severe diseases (i.e., spinal cord lesion, dementia, 
and CVA) were assigned the lowest health and high-
est WTP mean values. By contrast, less severe diseases 
were assigned the highest health and lowest WTP mean 
values. Although the respondents exhibited a high posi-
tive WTP for all the disease scenarios, a zero WTP indi-
cated that less severe diseases (e.g., allergic rhinitis, otitis 
media, and migraine) acquired less WTP preference. The 
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rate of non-traders and respondents with zero WTP 
somewhat confirm the effect of disease severity. For 
example, in mild diseases such as allergic rhinitis, 72% 
of respondents were non-traders while in the spinal cord 
scenario; the number is only 3%. On the other hand, 
although the majority of individuals had positive WTP in 
diseases (82% and 93%), the mean WTP value for spinal 
cord is 19 times of allergic rhinitis’ value.
Another interesting point associated with the trad-
ing behavior of respondents to scarify time or money is 
people are unwilling to scarify life time particularly in 
mild disease states, while the money is acceptable even 
small amounts. An example scenario is eczema, 63% of 
responders were non-traders while only 16% of them 
have zero WTP.
Mean WTP for QALY in 12 disease scenarios
Table 4 shows the mean values of WTP for QALY in the 
12 disease scenarios. The values varied depending on the 
severity of a disease and the instruments used to identify 
health preferences. In all the health preference meas-
ures, the respondents unanimously assigned the highest 
WTP value for a QALY gained to the CVA, spinal cord 
lesion, and dementia scenarios. The lowest was accorded 
to the back and neck pain and allergic rhinitis scenarios. 
Insofar as it is necessary to select one value to apply in 
the health policy context, the QALY value derived with 
TTO is more preferable to that obtained using VAS [31]. 
Moreover, we believe the TTO-adjusted technique is 
more desirable than the 10-year TTO technique because 
of its conformity with individual remaining expected life 
time. On these bases, a range of US$1032 to US$2666 can 
be selected as the most suitable mean WTP for QALY—
from the perspective of Tehran’s citizens. This range 
would reflect monetary value of one QALY gained from 
improvement in the quality of life among individuals suf-
fering from chronic mild to severe diseases. The ratios of 
WTP for QALY in relation to GDP per capita across the 
different scenarios are also listed in Table 4. These values 
were less than the one local GDP per capita of Iran in 
2014.
For each disease scenario, regression analysis using 
the Heckman selection model was performed to exam-
ine WTP for QALY-related factors, including individual 
characteristics and health histories [29, 30]. The signifi-
cant variables are reported in Table  5. The results indi-
cated that although the variables (except educational 
level) varied across different disease scenarios, a high 
health state valuation for target diseases, high monthly 
household cost group (as a proxy for income), high edu-
cational level, and being married were generally associ-
ated with high WTP for QALY.
Discussion
Our results showed that Iran’s general public was will-
ing to pay for one QALY but that such willingness var-
ied depending on disease severity and health preference 
instrument. Thus, more severe health states were associ-
ated with high WTP for QALY. The best estimated values 
ranged from US$1032 to US$2666. The lower limits of 
the range was obtained for the back and neck pain sce-
narios, followed by the allergic rhinitis scenario, and the 
upper limits were derived for the CVA scenario, followed 
by the spinal cord lesion scenario. Although the values 
differed depending on disease scenario, all of them were 
equal 0.22–0.56 of Iran’s local GDP per capita in 2014, i.e. 
less than the one. This is while, in the PC method, a bid 
range is designed to be wide enough to cover a GDP per 
capita of 0.07–17.5. Therefore, the method cannot drive 
individuals to state values lower than the aforementioned 
bid range.
In parallel with the present research, two studies on 
WTP for QALY were performed from the perspective of 
heart disease and diabetic patients [32, 33]. These groups 
were chosen because of the fact that cardiovascular 
Table 2 Sample characteristics
No. of respondents 1002
Mean age (year) (std. dev.) 43.36 (15.6)
Range (year) 18–79
Male gender (%) 408 (40.7)
Married (%) 731 (71.2)
Head of household (%) 372 (37.1)
Household size (std. dev.) 3.3 (1.2)
Education
 Elementary education ≤ 5 years 218 (21.8)
 Secondary education ≤ 8 years 107 (10.7)
 High school diploma ≤ 12 years 348 (34.8)
 University education 328 (32.7)
Monthly household cost group (US$)
 Less than 167 248 (24.7)
 167–333 473 (47.2)
 333–667 232 (23.1)
 667–1000 29 (2.9)
 More than 1000 20 (2.0)
Hospitalization and near-death experience from a year before
 Individual experience (%) 109 (10.9)
 Family member experience (%) 131 (13.0)
 Near-death experience (%) 50 (5)
Having a chronic disease
 Individual experience (%) 61 (6.1)
 Family member experience (%) 102 (10.2)
 Concurrent 41 (4.1)
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diseases and diabetes are often stated as the two increas-
ingly costly health problems in Iran, with the former 
being a serious disease with fatal consequences and the 
latter being a chronic disease with disabling complica-
tions [34]. The highest monetary values of QALY were 
US$3599 and US$4453 for cardiovascular diseases and 
diabetes, respectively. Although the mean values derived 
from the patients were greater than the upper value 
obtained from the general public [35], the patients’ pref-
erences align with society’s preference, which is less than 
one GDP per capita. The elicited values raise a major 
issue in employing an appropriate CE threshold, that is, 
a policy issue related to the WHO’s recommendation on 
using less than three GDP per capita as a CE threshold 
[13]. This is the most important policy challenge in the 
context of Iran health system because no evidence has 
been provided on the link or comparison between WTP 
per QALY and the WHO CE threshold in the country. 
This points to a policy challenge that concerns the appro-
priateness of the WHO’s recommendation on choosing 
cost-effective interventions, particularly for any coun-
tries with limited resources or unsustainable such as oil-
dependent economies.
More interesting, our empirical results on inappropri-
ateness of WHO CE threshold is in the same line with a 
study of woods et al. on estimating relationship of coun-
tries GDP per capita and CE threshold value based on 
their income level. It revealed the appropriate range for 
low,- middle and middle,-high income countries as 0.1–
0.51 and 0.18–0.71 GDP per capita, accordingly [18]. So, 
regarding the concerns around employing WHO recom-
mendation in policy making context including debates on 
its value derivation and relationship with country GDP 
per capita-, developing context-specific thresholds value 
by national health care system through considering soci-
ety priorities preferences and also examining it compared 
with WHO CE threshold value to establish a reasonable 
local CE value are recommended [16–18]. And use GDP 
per capita only as a criterion for updating the elicited CE 
threshold value.
Finally, it is essential to remind that this study inves-
tigate society preferences for interventions which 
improving quality of life, so the recommended range for 
life-saving interventions may be differ and higher. As a 
systematic review by Nimdet showed that the average 
ratio of WTP per QALY and GDP per capita for improv-
ing quality of life was 0.59, which is significantly lower 
than the ratio of life extension or life-saving treatments 
(2.03) [36].
Conclusion
In view of the policy argument discussed above, the gen-
eral public’s perspective was that the monetary value of 
QALY for treatments meant to improve quality of life was 
less than one GDP per capita. This value may differ from 
the value of QALY for life-prolonging or life-saving inter-
ventions because of the exclusion of the risk of death in 
our valuation [35]. A recent study by Viyanchi on select-
ing reimbursement criteria from the viewpoint of Iranian 
health decision makers illustrated that life-threatening 
conditions are the most important factors that should 
be considered when deciding on health insurance reim-
bursements before pharmacoeconomic evaluations [37]. 
Therefore, the range determined in the current work is 
recommend as a guide only for the adoption of interven-
tions intended to improve quality of life. We suggest that 
other researchers carry out studies that estimate the CE 
threshold for interventions in life-threatening diseases or 
formulate transparent policies, such as the National Insti-
tute for Health and Care Excellence’s end of life policy, in 
such contexts [38].
Additional files
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